Pharmaceuticals
Eli Lilly’s big GLP-1 investment — plus, what we want from 4 portfolio stock earnings
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. Wall Street was bouncing higher Friday after, as Jim Cramer put it, a “really bad day” in the prior session. Thursday’s late-day decline happened as bond yields rose on […]
Read More
Here’s how U.S. health officials are responding to bird flu in humans after second case
Cows are seen standing in a feedlot on June 14, 2023 in Quemado, Texas. Brandon Bell | Getty Images U.S. health officials are monitoring and preparing to combat bird flu in humans, even as they stress that the risk to the general public remains low. A strain of bird flu called H5N1 has been confirmed […]
Read More
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Eli Lilly on Friday said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana to boost supply of its highly popular weight loss drug Zepbound, diabetes treatment […]
Read More
This up-and-coming cancer treatment could be a $25 billion market opportunity — it’s already a hotbed for M&A
Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 […]
Read More
A corner of the cancer therapy market is heating up—Here are the names investors need to know
There’s been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor. There are currently two products on the market from Novartis and a slew of clinical […]
Read More
Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts
Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. Kena Betancur | Corbis News | Getty Images Pfizer on Wednesday said it has launched a new multi-year program to reduce costs as it works to rebound from the rapid decline of its Covid business. The announcement is in addition […]
Read More
JPMorgan states there is a new GLP-1 drug participant and its shares can rally 80%
Composition Therapeutics is an overlooked player in the GLP-1 current market, and could 1 working day boast a aggressive products and go up versus Eli Lilly and the like, according to JPMorgan. Analyst Hardik Parikh initiated research coverage on the clinical stage drug developer with an chubby rating and $65 value concentrate on, implying 82% […]
Read More
Eli Lilly stock hits new highs after a regulatory win in China. This is a big deal
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. The Nasdaq edged lower Tuesday, pulling back from record highs the session before. Jim Cramer described the market as overall “benign,” while the S & P 500 and Dow also […]
Read More
FDA approves Amgen’s treatment for most deadly form of lung cancer
The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images The Food and Drug Administration on Thursday approved Amgen‘s therapy for patients with the most deadly form of lung cancer. The agency cleared the drug, which will be marketed under the name Imdelltra, as a second or later line of treatment […]
Read More
Roche says weight loss drug shows promising results in early trial
A logo at the Roche Holding AG headquarters in Basel, Switzerland, on Thursday, Feb. 1, 2024. Bloomberg | Getty Images Roche on Thursday said its experimental weight loss drug showed promising results in an early-stage trial, boosting the company’s bid to compete in the booming market for those treatments. The Swiss company joined a slate of […]
Read More